Amalgamated Bank’s Sigilon Therapeutics, Inc. Common Stock SGTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-150
Closed -$3K 3293
2022
Q1
$3K Buy
+150
New +$3.34K ﹤0.01% 3050

Other funds holding SGTX

Amalgamated Bank's SGTX Position: Q2 2022 in Review

Amalgamated Bank sold out of Sigilon Therapeutics, Inc. Common Stock (SGTX) in Q2 2022, closing a stake of 150 shares — an estimated $3K sold.

Amalgamated Bank first reported a position in SGTX in Q1 2022 and held it in 1 quarter. The position peaked at $3K in Q1 2022. 37 funds tracked by Wall St. Rank hold SGTX as of Q2 2022.

  • Amalgamated Bank reported no remaining Sigilon Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Amalgamated Bank sold 150 Sigilon Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $3K.
  • Amalgamated Bank first reported a position in Sigilon Therapeutics, Inc. Common Stock in Q1 2022 and held it in 1 quarter.
  • Amalgamated Bank's Sigilon Therapeutics, Inc. Common Stock position peaked at $3K in Q1 2022.
  • 37 funds tracked by Wall St. Rank held Sigilon Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Amalgamated Bank's 13F filing for Q2 2022, filed 15 Aug 2022.